Miocrbot Medical® CEO to Discuss Recent FDA Clearance of the LIBERTY® Endovascular Robotic System
Microbot Medical (NASDAQ:MBOT) announces that CEO Harel Gadot will participate in a livestream interview on Benzinga All Access on September 24, 2025, at 10:45am ET. The discussion will focus on the company's recent FDA 510(k) clearance for the LIBERTY® Endovascular Robotic System, which was received on September 8, 2025.
During the interview, Mr. Gadot will outline the company's commercialization strategy for LIBERTY® in the U.S. market and discuss how this innovative system aims to transform the peripheral endovascular space.
Microbot Medical (NASDAQ: MBOT) annuncia che il CEO Harel Gadot parteciperà a un'intervista in diretta su Benzinga All Access il 24 settembre 2025 alle ore 10:45 ET. La discussione si concentrerà sull'autorizzazione FDA 510(k) per il LIBERTY® Endovascular Robotic System, ottenuta l'8 settembre 2025.
Durante l'intervista, il signor Gadot illustrerà la strategia di commercializzazione del LIBERTY® nel mercato statunitense e discuterà di come questo sistema innovativo miri a trasformare lo spazio endovascolare periferico.
Microbot Medical (NASDAQ: MBOT) anuncia que el CEO Harel Gadot participará en una entrevista en directo en Benzinga All Access el 24 de septiembre de 2025 a las 10:45 a. m. ET. La conversación se centrará en la reciente autorización FDA 510(k) para el LIBERTY® Endovascular Robotic System, obtenida el 8 de septiembre de 2025.
Durante la entrevista, el Sr. Gadot presentará la estrategia de comercialización del LIBERTY® en el mercado estadounidense y discutirá cómo este sistema innovador pretende transformar el ámbito endovascular periférico.
Microbot Medical(NASDAQ: MBOT)의 CEO 하렐 가도트가 2025년 9월 24일 동부 표준시 10:45에 Benzinga All Access에서 라이브 인터뷰에 참석한다고 발표합니다. 대화의 초점은 LIBERTY® Endovascular Robotic System의 최근 FDA 510(k) 승인에 맞춰 2025년 9월 8일에 취득한 내용입니다.
인터뷰 동안 가도트 회장은 LIBERTY®의 미국 시장에서의 상용화 전략을 제시하고, 이 혁신적인 시스템이 말초 혈관 내시경 영역을 어떻게 변화시킬지에 대해 논의할 예정입니다.
Microbot Medical (NASDAQ: MBOT) annonce que le PDG Harel Gadot participera à une interview en direct sur Benzinga All Access le 24 septembre 2025 à 10h45 ET. La discussion portera sur l'homologation FDA 510(k) du LIBERTY® Endovascular Robotic System, obtenue le 8 septembre 2025.
Au cours de l’interview, M. Gadot exposera la stratégie de commercialisation du LIBERTY® sur le marché américain et expliquera comment ce système innovant est destiné à transformer l’espace endovasculaire périphérique.
Microbot Medical (NASDAQ: MBOT) gibt bekannt, dass CEO Harel Gadot an einem Livestream-Interview bei Benzinga All Access am 24. September 2025 um 10:45 Uhr ET teilnehmen wird. Im Mittelpunkt der Diskussion steht die jüngste FDA 510(k)-Freigabe für das LIBERTY® Endovascular Robotic System, die am 8. September 2025 erteilt wurde.
Während des Interviews wird Herr Gadot die Markteinführungsstrategie von LIBERTY® im US-Markt skizzieren und erläutern, wie dieses innovative System den peripheren endovaskulären Bereich transformieren soll.
Microbot Medical (ناسداك: MBOT) تُعلن أن الرئيس التنفيذي هاريل جادو سيسهم في مقابلة بث مباشر عبر Benzinga All Access في 24 سبتمبر 2025 الساعة 10:45 صباحًا بتوقيت شرق الولايات المتحدة. ستتركز المناقشة على ترخيص FDA 510(k) الأخير لـ LIBERTY® Endovascular Robotic System، الذي مُنح في 8 سبتمبر 2025.
خلال المقابلة، سيعرض السيد جادو إستراتيجية تسويق LIBERTY® في السوق الأمريكية وسيناقش كيف يهدف هذا النظام المبتكر إلى إحداث تحول في مجال الشرايين الطرفية.
Microbot Medical（纳斯达克股票代码：MBOT）宣布首席执行官哈雷尔·加多特将于 2025年9月24日东部时间上午10:45 在 Benzinga All Access 的直播访谈中出席。讨论将聚焦于该公司最近获取的 FDA 510(k) 授权，适用于 LIBERTY® Endovascular Robotic System，授权日期为 2025年9月8日。
在访谈中，加多特先生将概述 LIBERTY® 在美国市场的商业化策略，并讨论这套创新系统如何旨在改变周边血管内科领域。
- None.
- None.
Livestream Interview Can be Viewed on September 24th at 10:45am ET at Benzinga All Access Live
HINGHAM, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of the innovative LIBERTY® Endovascular Robotic System, announces that its Chief Executive Officer, Harel Gadot, will be interviewed on Benzinga All Access at 10:45am ET on Wednesday, September 24, 2025. The live interview can be viewed at: Benzinga All Access Live. Mr. Gadot will discuss the recent FDA clearance of Microbot Medical’s LIBERTY®, and how the Company has planned for commercialization in the U.S. as it redefines the peripheral endovascular space with LIBERTY®.
On September 8, 2025, the Company announced it received FDA 510(k) clearance for commercialization of the LIBERTY® Endovascular Robotic System.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a breakthrough medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Learn more at www.microbotmedical.com and connect on LinkedIn and X.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of future regulatory pathways and future regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
FAQ
When did Microbot Medical (MBOT) receive FDA clearance for the LIBERTY® Endovascular Robotic System?
What will Microbot Medical's CEO discuss in the Benzinga All Access interview?
When and where can investors watch Microbot Medical's CEO interview?
What is the LIBERTY® system by Microbot Medical (MBOT)?
